Novonesis A/s Class B · OMXCOP:NSIS_B

Novonesis A/s Class B — Shareholder Meeting (2026)

64 slides from Novonesis A/s Class B's shareholder meeting presentation, 2026

Slide 2: Cees de Jong, Chair of the Board
Cees de Jong Chair of the Board
Slide 3: Board of Directors
Board of Directors Cees Heine Lise Monila Kasim Kevin Morten Otto Kim de Jong Dalsgaard Kaae Kothari Kutay Lane A. Sommer Stratton Chair of the Board Vice Chair Robert Lars Bo Preben Frederikke Nøddeskov Køppler Nielsen Rose Jensen Employee Employee Spenner representative representative Employee Emp
Slide 4: Executive Leadership Team
Executive Leadership Team Ester Baiget Rainer Lehmann Tina Sejersgård Fanø Claus Crone Fuglsang CEO CFO EVP, Planetary Health Biosolutions Chief Scientific Officer Anders Lund Henrik Jørck Nielsen Morten E. Rasmussen Andrew Taylor Chief Operating Officer EVP, Human Health Biosolutions & Strategy EVP
Slide 5: Our auditors
Our auditors —_ hovonesis
Slide 7: Anders Ørjan Jensen, Chair of the meeting
Anders Ørjan Jensen Chair of the meeting
Slide 8: hovonesis
hovonesis
Slide 9: Agenda
Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2. Presentation and approval of the audited Annual Report for 2025 3. Resolution on distribution of profit in accordance with the approved Annual Report 4. Presentation and advisory vote on the Remunerati
Slide 11: Delivering on our promises
Deliverin g on our promises Dairy Biogas Beverages Meat Plant-based foods Early-life nutrition Novel proteins Dietary supplements Animal health Pet care Textile Leather Pulp & paper Future chemicals Laundry Oils & fats Sustainable plastics Biodiesel Carbon capture Bioethanol Dish washing Home cleani
Slide 12: Strong 2025 results
S trong 2025 results 7% Organic 37.1% Adjusted sales growth EBITDA margin
Slide 13: Milestones 2025
Milestones 2025 Acquisition of Launched 33 dsm-firmenich animal new innovations feed enzyme business Sourced 100% of Launched our electricity from 2030 strategy renewable sources
Slide 14: Delivering on the integration
Delivering on the integration Cost synergy targets Sales synergies Strong employee reached one year on track engagement ahead of time
Slide 15: Biosolutions are an enabler of a more stable and resilient future
Biosolutions are an enabler of a more stable and resilient future By 2035, biosolutions could create globally EUR ~900 billion in economic value 5 million new jobs Copyright © 2026 Novonesis Group. All rights reserved.
Slide 16: Pure biology player
Pure biology player Customer centricity Innovation leadership World-class scale
Slide 17: Shareholders and shareholder returns
Shareholders and shareholder returns Share price performance compared to peer group and OMXC20 index ~100,000 120 110 shareholders 100 90 ~70% 80 70 of B shares held internationally 60 12/30/24 01/30/25 02/28/25 03/31/25 04/30/25 05/31/25 06/30/25 07/31/25 08/31/25 09/30/25 10/31/25 11/30/25 Novones
Slide 18: Creating shareholder value
Creating shareholder value Total dividend for the financial results 2025 at DKK 6.50 / EUR 0.87 per share Interim dividend paid in August 2025 Proposed dividend DKK 2.25 / EUR 0.30 DKK 4.25 / EUR 0.57
Slide 19: Remuneration of the Board of Directors
Remuneration of the Board of Directors • Based on a fixed fee structure • In 2025, the Board of Directors received a total remuneration of 1.7 million EUR, compared to 1.8 million EUR in 2024 • Remuneration overall decreased in 2025 due to reduction in shareholder-elected Board members • More inform
Slide 20: Remuneration of the Executive Management
Remuneration of the Executive Management The total remuneration of the Executive Management in 2025 amounted to EUR 8.9 million compared to EUR 9.7 million in 2024. Short-term incentive 2025 Short-term incentive 2026 • Organic sales growth • Same target structure as the 2025 program • Adjusted EBITD
Slide 21: Board evaluation in 2025
Board evaluation in 2025 • A well-functioning Board with good collaboration between the Board and the Executive Leadership Team • Evaluation included The Board and The Executive Leadership Team and consisted of a structured questionnaire, followed by individual interviews • In 2026, focus is on stre
Slide 24: Biological building blocks of the future
Biological building blocks of the future
Slide 25: Delivering solid organic sales growth
Delivering solid organic sales growth 7% Organic sales growth
Slide 26: Strong adjusted EBITDA-margin and cash flow
Strong adjusted EBITDA-margin and cash flow 37.1% Adjusted EBITDA margin EUR M 770 Free cash flow before acquisitions
Slide 27: Food & Health Biosolutions
Food & Health Biosolutions Food & Health Biosolutions revenue 1,867 MEUR Total organic sales growth 26% Organic sales growth 8% 8% Food & Beverages 10% 74% Human Health % of sales 2025 12M figures are compared to pro forma numbers
Slide 28: Planetary Health Biosolutions
Planetary Health Biosolutions Planetary Health Biosolutions revenue 2,290 MEUR Total organic sales growth Organic sales growth 6% 7% 35% Household Care 65% 6% Agriculture, Energy and Tech % of sales 2025 12M figures are compared to pro forma numbers
Slide 29: Continue to deliver innovative solutions today and tomorrow
Continue to deliver innovative solutions today and tomorrow 33 11% 25% >200 new innovations of sales is of sales in 2025 from projects in launched invested in R&D products launched in innovation pipeline the last five years
Slide 30: AI - Strengthening our competitive edge
AI - Strengthening our competitive edge
Slide 31: A thriving organization
A thriving organization 8.6 Employee engagement score In the top 10% of companies using the same measurement framework
Slide 32: We reached all six sustainability targets
We reached all six sustainability targets 67% 100% 8.4% reduction of greenhouse renewable more water saved gas emissions electricity sourced or recycled 1.4 100% 20 billion Lost Time Injury of biomass waste liters of water Frequency with absence managed circularly restored
Slide 33: GROW: 2030 strategy targets
GROW: 2030 strategy targets 6-9% Organic sales CAGR ~39%Adjusted ~16% Adjusted ROIC EBITDA margin excluding goodwill 75% Scope 1+2 by 2030* ≥40% Gender parity by 2030** *Reduction from 2018 baseline ** In senior management positions
Slide 34: 2026 outlook
2026 outlook 5-7% Organic sales growth 37-38% Adjusted EBITDA margin
Slide 35: The era of biosolutions is now
The era of biosolutions is now
Slide 36: Thank you
Thank you
Slide 38: Agenda
Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2. Presentation and approval of the audited Annual Report for 2025 3. Resolution on distribution of profit in accordance with the approved Annual Report 4. Presentation and advisory vote on the Remunerati
Slide 39: Agenda
Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2. Presentation and approval of the audited Annual Report for 2025 3. Resolution on distribution of profit in accordance with the approved Annual Report 4. Presentation and advisory vote on the Remunerati
Slide 40: Agenda
Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2. Presentation and approval of the audited Annual Report for 2025 3. Resolution on distribution of profit in accordance with the approved Annual Report 4. Presentation and advisory vote on the Remunerati
Slide 41: Agenda
Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2. Presentation and approval of the audited Annual Report for 2025 3. Resolution on distribution of profit in accordance with the approved Annual Report 4. Presentation and advisory vote on the Remunerati
Slide 42: Agenda
Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2. Presentation and approval of the audited Annual Report for 2025 3. Resolution on distribution of profit in accordance with the approved Annual Report 4. Presentation and advisory vote on the Remunerati
Slide 43: 5. Resolution on remuneration of the Board of Directors
5. Resolution on remuneration of the Board of Directors Base fee to Board of Directors • 3% increase in the base fee from the level in 2025 • Base fee of DKK 581,744 Supplementary fees • The chairs of board committees will each receive a supplementary fee of 1.0 times the base fee • The members of b
Slide 44: Agenda
Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2. Presentation and approval of the audited Annual Report for 2025 3. Resolution on distribution of profit in accordance with the approved Annual Report 4. Presentation and advisory vote on the Remunerati
Slide 46: Proposed Board of Directors
Proposed Board of Directors Cees Heine Lise Monila Kasim Kevin Morten Otto Kim de Jong Dalsgaard Kaae Kothari Kutay Lane A. Sommer Stratton Chair of the Board Vice Chair Robert Lars Bo Preben Frederikke Nøddeskov Køppler Nielsen Rose Jensen Employee Employee Spenner representative representative Emp
Slide 48: Cees de Jong
Cees de Jong Standing for re-election as Chair of the Board
Slide 49: Heine Dalsgaard
Heine Dalsgaard Standing for re-election as Vice Chair
Slide 50: Re-election of board members
Re-election of board members Lise Monila Kasim Kevin Morten Otto Kim Kaae Kothari Kutay Lane A. Sommer Stratton
Slide 51: Employee-elected board members after the Annual General Meeting 2026
Employee-elected board members after the Annual General Meeting 2026 Robert Nøddeskov Lars Bo Preben Frederikke Jensen Køppler Nielsen Rose Spenner
Slide 52: Agenda
Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2. Presentation and approval of the audited Annual Report for 2025 3. Resolution on distribution of profit in accordance with the approved Annual Report 4. Presentation and advisory vote on the Remunerati
Slide 53: 9. Election of auditor
9. Election of auditor —_ hovonesis
Slide 54: Agenda
Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2. Presentation and approval of the audited Annual Report for 2025 3. Resolution on distribution of profit in accordance with the approved Annual Report 4. Presentation and advisory vote on the Remunerati
Slide 55: 10a. Renewal of authorization to implement capital increases
10a. Renewal of authorization to the Board of Directors to implement capital increases To renew the Board's authorization to increase the company's share capital – both with and without pre- emptive rights for existing shareholders – and to issue warrants. All three authorizations are proposed to be
Slide 56: 10b. Renewal of authorization to acquire treasury shares
10b. Renewal of authorization to the Board of Directors for the company to acquire treasury shares The authorization is proposed to be extended to April 30, 2027, and will allow the company to repurchase own shares corresponding to 10% of the share capital. The authorization will be subject to a hol
Slide 57: 10c. Authorization for distribution of extraordinary dividend
10c. Authorization to the Board of Directors for distribution of extraordinary dividend The Board to be authorized to distribute extraordinary dividends, as described in more detail in the convening notice.
Slide 58: 10d. Amendment of location of general meetings
10d. Amendment of location of general meetings due to new regional naming According to Article 7.2 of the Articles of Association, general meetings shall be held in the Capitol Region of Denmark. This region will be combined into a new region, the Region of Eastern Denmark, with effect from January
Slide 59: Agenda
Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2. Presentation and approval of the audited Annual Report for 2025 3. Resolution on distribution of profit in accordance with the approved Annual Report 4. Presentation and advisory vote on the Remunerati
Slide 60: 11a. Proposal from shareholder
11a. Proposal from shareholder The Board of Directors does not support the proposal, as the Further, Novonesis has established governance and subject matter is governed by applicable law and Novonesis’ procedures in matters regarding potential violations of law, existing policy framework. The Board’
Slide 61: Agenda
Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2. Presentation and approval of the audited Annual Report for 2025 3. Resolution on distribution of profit in accordance with the approved Annual Report 4. Presentation and advisory vote on the Remunerati
Slide 62: Agenda
Agenda 1. The Board of Directors’ report on the Company’s activities in the past financial year 2. Presentation and approval of the audited Annual Report for 2025 3. Resolution on distribution of profit in accordance with the approved Annual Report 4. Presentation and advisory vote on the Remunerati

Novonesis — Shareholder Meeting (2026) on 6ix

Novonesis A/s Class B — Shareholder Meeting (2026)

Slide 1: Annual General Meeting 2026

Slide 2: Cees de Jong, Chair of the Board

Slide 3: Board of Directors

Slide 4: Executive Leadership Team

Slide 5: Our auditors

Slide 6: Annual General Meeting 2026

Slide 7: Anders Ørjan Jensen, Chair of the meeting

Slide 8: hovonesis

Slide 9: Agenda

Slide 10: Annual General Meeting 2026

Slide 11: Delivering on our promises

Slide 12: Strong 2025 results

Slide 13: Milestones 2025

Slide 14: Delivering on the integration

Slide 15: Biosolutions are an enabler of a more stable and resilient future

Slide 16: Pure biology player

Slide 17: Shareholders and shareholder returns

Slide 18: Creating shareholder value

Slide 19: Remuneration of the Board of Directors

Slide 20: Remuneration of the Executive Management

Slide 21: Board evaluation in 2025

Slide 22: Thank you

Slide 23: Annual General Meeting 2026

Slide 24: Biological building blocks of the future

Slide 25: Delivering solid organic sales growth

Slide 26: Strong adjusted EBITDA-margin and cash flow

Slide 27: Food & Health Biosolutions

Slide 28: Planetary Health Biosolutions

Slide 29: Continue to deliver innovative solutions today and tomorrow

Slide 30: AI - Strengthening our competitive edge

Slide 31: A thriving organization

Slide 32: We reached all six sustainability targets

Slide 33: GROW: 2030 strategy targets

Slide 34: 2026 outlook

Slide 35: The era of biosolutions is now

Slide 36: Thank you

Slide 37: Annual General Meeting 2026

Slide 38: Agenda

Slide 39: Agenda

Slide 40: Agenda

Slide 41: Agenda

Slide 42: Agenda

Slide 43: 5. Resolution on remuneration of the Board of Directors

Slide 44: Agenda

Slide 45: Annual General Meeting 2026

Slide 46: Proposed Board of Directors

Slide 47: Annual General Meeting 2026

Slide 48: Cees de Jong

Slide 49: Heine Dalsgaard

Slide 50: Re-election of board members

Slide 51: Employee-elected board members after the Annual General Meeting 2026

Slide 52: Agenda

Slide 53: 9. Election of auditor

Slide 54: Agenda

Slide 55: 10a. Renewal of authorization to implement capital increases

Slide 56: 10b. Renewal of authorization to acquire treasury shares

Slide 57: 10c. Authorization for distribution of extraordinary dividend

Slide 58: 10d. Amendment of location of general meetings

Slide 59: Agenda

Slide 60: 11a. Proposal from shareholder

Slide 61: Agenda

Slide 62: Agenda

Slide 63: Annual General Meeting 2026

Slide 64: Thank you and see you again in 2027